GlassScriptPhysician profile
Ghurulakshmi Moorthy
NPI 1639434814
$8,033.99
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $2,354 · 2021: $1,774 · 2022: $1,961 · 2023: $827 · 2024: $71.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,162.88 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,020.55 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $565.60 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Insulet Corporation | $505.21 | 2019-2023 | Omnipod |
| Abbott Laboratories | $497.29 | 2019-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $429.66 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $426.80 | 2020-2023 | Gvoke Hypopen |
| Amgen INC. | $405.51 | 2019-2023 | Repatha |
| Abbvie INC. | $367.76 | 2019-2022 | |
| Corcept Therapeutics | $267.64 | 2019-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.89 | 2019-2023 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $259.93 | 2022-2023 | |
| Amarin Pharma, INC. | $201.82 | 2019-2022 | |
| Horizon Therapeutics Plc | $184.44 | 2021-2023 | Tepezza |
| Radius Health, INC. | $145.73 | 2019-2023 | Tymlos |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $143.02 | 2021-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $129.92 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.88 | 2019-2021 | |
| Ibsa Pharma INC. | $122.50 | 2020-2023 | Tirosint, Licart |
| Dexcom, INC. | $116.29 | 2019-2023 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $107.40 | 2022-2023 | |
| Esperion Therapeutics, INC. | $89.71 | 2020-2021 | |
| Embecta Corp. | $77.82 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amneal Pharmaceuticals LLC | $63.82 | 2019-2023 | Unithroid |
| Antares Pharma, INC. | $58.47 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Companion Medical, INC. | $46.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.12 | 2022 | |
| Medtronic Minimed, INC. | $32.35 | 2020 | |
| Pfizer INC. | $27.20 | 2019-2022 | |
| Becton, Dickinson and Company | $20.47 | 2022 | |
| Intuity Medical INC | $18.45 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Tolmar Pharmaceuticals, INC. | $14.34 | 2022 | |
| Recordati_rare_diseases_inc. | $14.33 | 2022 | |
| Eusa Pharma (US) LLC | $14.33 | 2022 | |
| Grt US Holding, INC. | $14.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.82 | 2021 | |
| Cequr Corporation | $13.00 | 2022 | |
| Nevro Corp. | $12.49 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghurulakshmi Moorthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.